Allogene Therapeutics publishes update to financial calendar
ALLO•Allogene Therapeutics will release third-quarter 2026 results on Nov. 5 after market close and hold a results call that day. A Nov. 9 webinar will review preliminary ALLO-329 Phase 1 autoimmune data, with initial RESOLUTION study results also scheduled for an ACR Convergence poster presentation.
1. Upcoming events
Allogene Therapeutics will release third-quarter 2026 financial results on Nov. 5 after market close, followed by a results conference call and business update at 2 p.m. PT/5 p.m. ET. On Nov. 9, a webinar at 6 a.m. PT/9 a.m. ET will review preliminary ALLO-329 Phase 1 autoimmune safety and efficacy data. Initial RESOLUTION study results will also appear in an ACR Convergence poster presentation from 10:30 a.m. to 12:30 p.m. ET that day.
